Focus Biomolecules

FOCUS on Drug Discovery. Lilly will acquire Scorpion Therapeutics' PI3Kalpha inhibitor program which includes STX-478 a differentiated and potentially best-in-class mutant-selective PI3Kalpha inhibitor which is currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. Read the Lilly News Release here. https://lnkd.in/gDQ-_4Tw Focus Biomolecules can supply STX-478 for research applications. For more info contact us https://lnkd.in/dG8wyUz6 #Cancerresearch #Smallmolecules #Pharmacology #Drugdiscovery

FOCUS on Reversal of Tau Pathology. In a January Communications Biology paper, Eric McGregor and coworkers showed that adiponectin receptor activation with the small molecule agonist, adiporon, cleared neurofibrillary tangles (NFTs) and rescued neuronal tauopathy-associated defects. Adiporon reduced levels of phospho-tau and lowered NFT burden via a mechanism involving the energy-sensing kinase AMPK and the growth-sensing kinase GSK3beta. ?The negative effects of NFTs on mitochondrial activity, ATP production and lipid stores were corrected revealing a network linking mitochondrial function and cellular maintenance processes that can be targeted via adiponectin receptors. The BBB permeability of adiporon is noteworthy. ? Access the full paper (open access) here https://lnkd.in/eUahiBzR Focus Biomolecules can supply Adiporon for research applications. https://lnkd.in/eVJdXy4W #Smallmolecules #Neurodegeneration #Pharmacology #Drugdiscovery

FOCUS on Bioactive Natural Products. In a February Nature Communications paper, Wang and coworkers showed that a sesquiterpenoid found abundantly in ginger, known as furanodienone, alleviated gut inflammation in a mouse model. They went on to show that furanodienone acted selectively as an agonist at the nuclear receptor PXR (Pregnane X Receptor). Orally administered furanodienone displayed potent PXR-dependant antiinflammatory activity that was colon-specific. The full paper (open access) can be found here. https://lnkd.in/enh_KKqv Focus Biomolecules can supply furanodienone for research applications. Contact us for more info: https://lnkd.in/dG8wyUz6 #Naturalproducts #Inflammationresearch #Pharmacology #Nuclearreceptors

FOCUS on New Drug Approvals. Last Friday the FDA granted full approval of Deciphera’s Romvimza? (Vimseltinib) for the treatment of symptomatic tenosynovial giant cell tumor (TGCT) in adult patients. Vimseltinib is a dual?inhibitor of c-FMS and c-Kit. Deciphera is a wholly owned subsidiary of Ono Pharmaceuticals. The FDA announcement can be found here: https://lnkd.in/g7iR78YW Announcement by Deciphera can be found here: https://lnkd.in/eFhfTqPj Focus Biomolecules can supply Vimseltinib for research applications. For more info contact us at: https://lnkd.in/dG8wyUz6 #smallmolecules #kinaseinhibitors #pharmacology #cancerresearch

FOCUS on New Drug Approvals. Yesterday the FDA approved SpringWorks Therapeutics' Mirdametinib (PD-325901) for the treatment of patients with neurofibromatosis type 1 with symptomatic plexiform neurofibromas in adults and children. Mirdametinib is a non-ATP-competitive MEK inhibitor first developed by Parke-Davis Pharmaceuticals. The FDA announcement can be found here: https://lnkd.in/gdEDxXN3 Announcement by SpringWorks can be found here: https://lnkd.in/gYQp8iBd Focus Biomolecules can supply Mirdametinib for research applications. For more info visit: https://lnkd.in/e6mbWRqW #Drugdiscovery #Pharmacology #Smallmolecules

FOCUS on drug discovery failure. Development of Risvodetinib for Parkinson's disease was halted following disappointing Phase II results. The drug, which is a potent and brain-penetrant c-Abl inhibitor, was being developed by Inhibikase Therapeutics which reported its findings in an SEC filing. The drug met safety and tolerability requirements but failed to demonstrate significant efficacy. Full story at BioSpace: https://lnkd.in/ezfc4nqX Inhibikase Therapeutics website: https://www.inhibikase.com Focus Biomolecules can supply Risvodetinib for research applications. Contact us for more information. https://lnkd.in/dG8wyUz6 #Drugdiscovery #Pharmacology #Smallmolecules #Parkinsonsdisease

FOCUS on New Drug Approvals. Yesterday the FDA approved Vertex Pharmaceutical's Suzetrigine (VX-548) for the treatment of moderate to severe acute pain in adults. Suzetrigine is a first-in-class non-opioid analgesic acting via Nav1.8 blockade. The FDA announcement can be found here: https://lnkd.in/dUUs3fxB Announcement by Vertex can be found here: https://lnkd.in/gNgYfk5B Focus Biomolecules can supply Suzetrigine for research applications. Contact us for more info. https://lnkd.in/dG8wyUz6 #Drugdiscovery #Pharmacology #Smallmolecules #Painresearch

FOCUS on elimination of senescent cancer cells. Researchers at the Netherlands Cancer Institute just reported in PNAS that they identified SLC25A23 as a vulnerability of senescent cancer cells. Suppressing SLC25A23 or treatment with salinomycin disrupted cellular calcium homeostasis, impaired oxidative phosphorylation and interfered with redox signaling. Treatment with salinomycin prompted a PANoptosis-like cell death in senescent cells which included apoptosis and two forms of immunogenic cell death: necroptosis and pyroptosis. https://lnkd.in/eqsYWyFD Focus Biomolecules offers salinomycin for research applications. For more info visit https://lnkd.in/e-xT6R7w #Cancerresearch #cellularsenescence #smallmolecules #cellbiology

Science’s 2024 "Breakthrough of the Year" is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months. The drug attaches to the lattice-like capsid proteins that shield the virus’s genetic material—a mechanism that could inspire other antivirals. Learn more about this year's #BOTY and other big advances in science: https://scim.ag/4g9ysmR Lenacapavir was developed by Gilead Sciences https://www.gilead.com/ Ask us about availability for research https://lnkd.in/dG8wyUz6 #smallmolecules #drugdiscovery #pharmacology

Focus on Drug Approvals. Today the FDA approved Ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer. Ensartinib is a potent and specific ALK inhibitor. FDA announcement can be found here: https://lnkd.in/gTX-gS4c Focus Biomolecules can supply Ensartinib for research applications. Contact us for more info. https://lnkd.in/dG8wyUz6 #Drugdiscovery #Cancerresearch #smallmolecules #Pharmacology